Bldg. 1 133
[Co-creation of seeds - The future of collaboration among industry, universities and government -]
Sunday, March 17, PM
(12:50-13:00)
2A5-24 Opening Remarks / Closing Remarks
(12:50) Opening Remarks (Mitsubishi Chemical Holdings Corporation) º URATA, Hisao
Chair: TSUJI, Ryotaro
(13:00-14:30)
2A5-25 ATP Special Invited Lecture
(13:00) The problem and solution of open innovation (HUB) º NISHINO, Kazumi
2A5-29 ATP Special Invited Lecture
(13:40) R&D-strategy of materials science and nanotechnology (JST) º NAKAYAMA, Tomohiro
2A5-33 ATP Incubation Time
(14:20)
Chair: ABE, Ryu
(14:30-17:40)
2A5-34 ATP Special Invited Lecture
(14:30) Graduate School for Industry-University-Government Co-Creation - Approach to Acceleration of Open Innovation - (Grad. Sch. Eng., Osaka Univ.) º KURASHIKI, Tetsuei
2A5-38 ATP Special Invited Lecture
(15:10) Chemistry, Connecting Diversity towards the New Innovation (JACI) º KATAOKA, Masaki
2A5-42 ATP Incubation Time
(15:50)
2A5-43 ATP Special Invited Lecture
(16:00) Amazing Creativity in Diversity-Oriented Japanese Way º DOMEN, Kay
2A5-47 Panel Discussion
(16:40) Co-creation of seeds --- The future of collaboration in chemistry --- (Mitsubishi Chemical Holdings Corporation; Showa Denko K.K.; Yushisozo; Grad. Sch. Eng., Osaka Univ.; ICR, Kyoto Univ.; Hiroshima Univ.)
[Innovative healthcare technologies]
Monday, March 18, PM
Bioventures based on new modalities
(13:00-13:10)
3A5-25 Opening Remarks / Closing Remarks
(13:00) Opening Remarks (Grad. Sch. Sci., The Univ. of Tokyo) º SUGA, Hiroaki
Chair: OHNO, Osamu
(13:10-15:00)
3A5-26 ATP Special Invited Lecture#
(13:10) Aptamer as a therapeutic middle molecule and its development to clinical trials (RIBOMIC) º NAKAMURA, Yoshikazu
3A5-30 ATP Invited Lecture
(13:50) Peptide Therapeutics and Antibody inducing Peptide (FunPep) º HIRAI, Akimitsu
3A5-33 ATP Incubation Time
(14:20)
3A5-34 ATP Invited Lecture
(14:30) Development of an Unnatural Peptide Drug Candidate CBP501 and Recent Paradigm Shifts in Oncology Drug Development (CanBas Co., Ltd.) º KAWABE, Takumi
Chair: YUNOMURA, Shuichi
(15:00-16:50)
3A5-37 ATP Invited Lecture
(15:00) Development of Telomelysin®, Telomerase dependent oncolytic virus (Oncolys BioPharma Inc.) º URATA, Yasuo
3A5-40 ATP Incubation Time
(15:30)
3A5-41 ATP Invited Lecture
(15:40) Expactations and Challenges of New Modality Medicinal Products from Pharmaceutical Business Point of View (Daiichi Sankyo Co., LTD.) º KUBO, Yuichi
3A5-44 ATP Invited Lecture
(16:10) Modulus Discovery: Networked drug discovery leveraging large-scale simulation technology º KIMURA, Roy, Suguru
3A5-47 ATP Incubation Time
(16:40)